Catalog No.
Product Name
Application
Product Information
Citations
-
Topo IIα Inhibitor
Topoisomerase IIα-IN-2 is a potent inhibitor of topoisomerase IIα, targeting the enzyme's DNA-binding activity. It demonstrates significant antiproliferative effects against various human cancer cell lines and induces substantial DNA damage. Additionally, Topoisomerase IIα-IN-2 effectively halts cancer cell progression at the G2/M phase, making it a valuable reagent for cancer research and therapeutic investigations. -
Topo I inhibitor
Fagopyrine is a potent inhibitor of DNA topoisomerase I (Topo I), an enzyme critical for DNA relaxation and transcription processes. Its ability to intercalate into DNA makes Fagopyrine a valuable tool in cancer research, particularly in studies involving tumor dynamics and photosensitization therapies. This compound can be instrumental in understanding the role of Topo I in tumor cell proliferation and response to treatment. -
Topoisomerase Inhibitor
A 9387 is a topoisomerase inhibitor that specifically targets Tn3 Resolvase, interrupting its role in site-specific recombination between directly repeated sequences. This compound effectively inhibits the binding of resolvase to the resolution site, thereby preventing the recombination process. A 9387 is valuable for research applications in genetic recombination and molecular biology studies focused on DNA manipulation and topological changes. -
Topoisomerase I Inhibitor
β-Glu-PAB(CH2NH2)-Exatecan is a selective inhibitor of topoisomerase I. It disrupts the topoisomerase I-DNA complex, preventing DNA strand rejoining, which leads to DNA breakage and subsequent apoptosis in cancer cells. This compound is specifically designed to be activated by β-glucuronidase, which is highly expressed in the tumor microenvironment, thereby activating Exatecan and enhancing its cytotoxicity. β-Glu-PAB(CH2NH2)-Exatecan serves as a valuable tool for cancer research, particularly in exploring targeted therapies. -
Topoisomerase I Inhibitor
Topoisomerase I-IN-19 is a potent inhibitor of Topoisomerase I, a critical enzyme involved in DNA replication and transcription. This compound facilitates the study of Topoisomerase I-mediated diseases, particularly in cancer research, by allowing for the evaluation of cell growth, apoptosis, and the therapeutic potential of Topoisomerase I inhibition. Its efficacy in modulating Topoisomerase I activity makes it a valuable tool for mechanistic studies and drug development in oncology. -
Topoisomerase II Inhibitor
Topoisomerase II Inhibitor 18 is a quinoxaline derivative that selectively inhibits topoisomerase II with an IC50 of 7.5 μM. This compound effectively suppresses cell proliferation and induces G1/S phase cell cycle arrest, leading to apoptosis in PC-3 cancer cells. It demonstrates significant antitumor activity, making it a valuable tool for cancer research applications focused on topoisomerase II modulation. -
DNA Topoisomerase Inhibitor
PNU-142586 sodium is a potent inhibitor of DNA topoisomerase 2-α (TOP2A) and DNA topoisomerase 2-β (TOP2B). This compound effectively disrupts DNA replication and transcription by preventing the binding of DNA to TOP2 and inhibiting ATP hydrolysis, resulting in antiproliferative and cytotoxic effects, including mitochondrial dysfunction. PNU-142586 sodium is primarily utilized in research investigating Linezolid-induced hematotoxicity and its underlying molecular mechanisms. -
Antitumor Agent
Piroxantrone is a potent anthrapyrazole antitumor agent that primarily targets DNA topoisomerase II. It exhibits significant cytotoxic effects on cancer cells, making it a valuable compound for research in oncological studies. However, it is important to note that Piroxantrone also displays cardiotoxicity, highlighting the need for careful evaluation in therapeutic applications. -
Topoisomerase II Inhibitor
Topoisomerase II inhibitor 6 is a potent and selective inhibitor of topoisomerase II, derived from tryptanthrin. This compound demonstrates significant antiproliferative activity across various tumor cell lines and effectively halts the cell cycle of CCRF-CEM cells at the G2 phase, while inducing DNA double-strand breaks (DSBs). Its robust mechanism of action makes Topoisomerase II inhibitor 6 a valuable reagent for cancer research and therapeutic investigations. -
Topoisomerase Inhibitor
Amonafide dihydrochloride is a potent inhibitor of topoisomerase II, functioning by disrupting the enzyme's binding to DNA and subsequently halting DNA and RNA synthesis. This compound exhibits significant cytotoxicity and is capable of inducing apoptotic signaling pathways. Notably, Amonafide dihydrochloride retains its efficacy in the context of P-glycoprotein-mediated multidrug resistance, making it a valuable tool for cancer research and development of therapies targeting resistant tumors. -
Resolvase Inhibitor
A1062 is a potent inhibitor of Tn3-encoded resolvase, exhibiting an IC50 in the micromolar range. This compound effectively suppresses the binding of resolvase proteins to their respective sites, thereby blocking resolvase-induced site-specific recombination. A1062 can be utilized in research applications focused on understanding site-specific recombination mechanisms and exploring genetic engineering strategies. -
DNA Topoisomerase Inhibitor
Pazelliptine is a potent DNA topoisomerase inhibitor that exhibits significant antitumor activity. By interfering with the enzyme's action, Pazelliptine can induce DNA damage and inhibit cellular proliferation, making it a valuable tool in cancer research. Its ability to disrupt critical cellular processes positions it as an important reagent for studying mechanisms of tumorigenesis and developing therapeutic strategies. -
Topoisomerase II Inhibitor
ARN24139 is a potent inhibitor of topoisomerase II, exhibiting an IC50 value of 7.3 μM. This compound demonstrates significant anti-proliferative effects on cancer cells and has shown an acceptable safety profile in vivo. ARN24139 is suitable for use in studies focused on cancer biology and therapeutic development targeting topoisomerase II-mediated pathways. -
Anticancer agent
Anticancer agent 216 (34A) is a Camptothecin derivative that selectively inhibits topoisomerase I, disrupting DNA replication and transcription. It demonstrates potent cytotoxicity with IC50 values of 9.6 nM in MCF-7 breast cancer cells and 11.6 nM in MDA-MB-231 cells. This compound is valuable for research applications focused on developing targeted therapies for breast cancer and understanding the mechanisms of tumor cell resistance. -
Topoisomerases I/II Inhibitor
Elomotecan is a potent inhibitor of topoisomerases I and II, classified as a camptothecin analog within the homocamptothecin family. This compound exhibits significant cytotoxic activity against various tumor cell lines, demonstrating enhanced efficacy compared to standard anticancer agents targeting the same mechanisms. Elomotecan's ability to interfere with DNA replication and repair makes it a valuable tool in cancer research and drug development. -
Antitumor Drug
Atiratecan is a proagent of the camptothecin analog CH0793076, primarily targeting tumor cells. It demonstrates significant antitumor activity in both breast cancer resistance protein (BCRP)-positive and -negative xenograft models in mice. Atiratecan is a valuable compound for research applications in cancer biology, particularly in exploring drug resistance mechanisms and developing new therapeutic strategies. -
DNA topoisomerase II Inhibitor
cis-THSG is a selective inhibitor of DNA topoisomerase II, demonstrating no activity against DNA topoisomerase I. This compound effectively suppresses the transcription of phosphoenolpyruvate carboxykinase (PEPCK), leading to reductions in blood glucose levels, improvement of glucose intolerance, and alleviation of insulin resistance in high-fat diet-induced diabetic male CF-1 mice. cis-THSG serves as a valuable tool for research into type 2 diabetes mellitus and the mechanisms of glucose metabolism. -
DNA Topoisomerase Inhibitor
Melicopidine is a DNA topoisomerase inhibitor derived from the acridone alkaloid family, sourced from the bark of Medicosma subsessilis. This compound demonstrates potential antitumor activity by binding to DNA and inhibiting the enzymatic activity of topoisomerases. It is applicable in various cancer research studies focusing on mechanisms of action related to DNA manipulation and repair processes. -
Topoisomerase-Ι Inhibitor
Camptothecin-20(S)-O-propionate hydrate is a potent topoisomerase I inhibitor. This compound is recognized for its significant anticancer properties, engaging in the modulation of DNA topology and inducing apoptosis in cancer cells. It is widely used in cancer research to explore mechanisms of chemotherapeutic action and to develop novel therapeutic strategies targeting topoisomerase I. -
Top I Inhibitor
BMS-250749 is a potent inhibitor of topoisomerase I (Top I) derived from the fluoroglycosyl-3,9-difluoroindolecarbazole class. It demonstrates significant cytotoxic effects and selectivity, exhibiting notable antitumor activity in Lewis lung cancer models. Additionally, BMS-250749 has shown broad-spectrum antitumor efficacy, outperforming CPT-11 in select preclinical xenograft studies. -
Topo II Inhibitor
Salvicine is a potent inhibitor of DNA topoisomerase II, exhibiting an IC50 of 3 μM. By targeting the ATPase domain of Topo II, Salvicine enhances its interaction with DNA, thereby inhibiting DNA degradation and ATP hydrolysis. This compound demonstrates significant anticancer properties, including the induction of DNA damage, the potential to overcome multidrug resistance, and the inhibition of tumor cell adhesion, making it a valuable tool for cancer research applications. -
Topoisomerase
(-)-Eleutherin is a pyranonaphthoquinone derivative that primarily targets DNA topoisomerase II, exhibiting potent cytotoxic activity. This compound induces significant DNA fragmentation, highlighting its efficacy in disrupting cellular integrity. Furthermore, (-)-Eleutherin demonstrates enhanced antioxidant properties, which may contribute to its therapeutic potential in various medicinal applications, making it a valuable candidate for cancer research and treatment strategies. -
Top II Inhibitor
A-74932 hydrochloride is a potent inhibitor of DNA topoisomerase II, a critical enzyme involved in DNA replication and transcription. By inhibiting the catalytic activity of mammalian topoisomerase II, A-74932 hydrochloride demonstrates significant antitumor activity. This compound is valuable for cancer research, particularly in studies focused on the modulation of topoisomerase function and the development of novel therapeutic strategies. -
Topoisomerase I Inhibitor
(±)-E-Homocamptothecin is a potent inhibitor of topoisomerase I, an enzyme critically involved in DNA replication and transcription. This compound is primarily utilized in cancer research, demonstrating significant potential in the study of tumor cell proliferation and resistance mechanisms. Its ability to interfere with DNA topology makes it a valuable tool in the exploration of therapeutic strategies targeting malignant cells. -
Anticancer agent
Anticancer agent 217 is a Camptothecin derivative targeting topoisomerase I, a crucial enzyme involved in DNA replication and repair. It demonstrates potent antitumor activity, with IC50 values of 6.2 nM in MCF-7 cells and 7.1 nM in MDA-MB-231 cells. This compound is suitable for research applications in cancer biology, particularly for studying the mechanisms of tumor cell proliferation and apoptosis. -
Anticancer agent
Anticancer agent 219 (P139) is a Camptothecin derivative that primarily targets and inhibits topoisomerase I, an essential enzyme in DNA replication and repair. This compound demonstrates significant anticancer activity, making it a valuable tool for the study of cancer biology. It is applicable in research areas focusing on tumor cell proliferation and apoptosis induction, providing insights into potential therapeutic strategies for cancer treatment. -
Topo IIα Inhibitor
Topoisomerase IIα-IN-1 is a selective inhibitor of topoisomerase IIα, a key enzyme involved in DNA strand separation and replication. This compound demonstrates significant antiproliferative activity against various human cancer cell lines, making it a valuable tool for cancer research. Its ability to disrupt DNA topology positions Topoisomerase IIα-IN-1 as a promising candidate for studies focused on tumorigenesis and therapeutic interventions in oncology. -
Topoisomerase Inhibitor
Huanglongmycin N is a potent inhibitor of DNA topoisomerase I, with an EC50 value of 14 μM. This compound disrupts the normal function of topoisomerase I, subsequently hindering DNA replication and transcription processes. Huanglongmycin N is valuable for research applications focused on cancer therapeutics and the study of DNA damage response mechanisms. -
Topo IIα Inhibitor
Topoisomerase IIα-IN-8 is an inhibitor of human DNA topoisomerase IIα (htIIα), characterized by an IC50 value of 462 ± 38.0 μM. This compound is utilized in research focused on unraveling the mechanisms of DNA topology modification and the role of topoisomerases in cellular processes. Its applications extend to studies in cancer biology, particularly in evaluating the effects of topoisomerase inhibition on cell proliferation and apoptosis. -
Topoisomerase
Camptothecin analog-1 is a potent inhibitor of topoisomerase I, a crucial enzyme involved in DNA replication and repair. This compound demonstrates significant anti-cancer activity by inducing DNA damage and promoting apoptosis in malignant cells. It is used in research to investigate mechanisms of tumorigenesis and explore novel therapeutic strategies in oncology. -
Topoisomerase Inhibitor
ACT-387042 is a potent bacterial topoisomerase inhibitor that exhibits broad-spectrum antibacterial activity against both Gram-positive and Gram-negative bacteria. It demonstrates efficacy against methicillin-resistant Staphylococcus aureus and penicillin- and fluoroquinolone-resistant Streptococcus pneumoniae. This compound is valuable for research applications focused on antibiotic resistance and the development of novel antibacterial therapies. -
Top1 Inhibitor
Indimitecan hydrochloride is a potent inhibitor of topoisomerase I (Top1), a key enzyme involved in DNA replication and repair. This compound exhibits significant anticancer activity by inducing DNA damage and inhibiting cellular proliferation in tumor cells. Indimitecan hydrochloride is utilized in cancer research to study mechanisms of drug action and to evaluate therapeutic strategies targeting Top1. -
Anticancer Agent
Anticancer Agent 214 is a Camptothecin derivative that exerts its cytotoxic effects by inhibiting topoisomerase I. This compound demonstrates potent antitumor activity, with IC50 values of 2.6 nM in MCF-7 cells and 15.7 nM in MDA-MB-231 cells. It is a valuable reagent for research focused on cancer biology and therapeutic development. -
Topoisomerase I Inhibitor
Topoisomerase I Inhibitor 6 is a potent inhibitor targeting Topoisomerase I. This compound effectively stabilizes the DNA-Top1 cleavage complex while exhibiting reduced cytotoxicity in non-cancerous cell lines. Its unique properties make it a valuable tool for cancer research, enabling the investigation of therapeutic mechanisms and potential applications in oncology. -
Anticancer Agent
N,N-Dimethyldoxorubicin is an analogue of the well-known anticancer agent doxorubicin, targeting DNA through intercalation. This compound exhibits potent cytotoxic activity against various tumor cell lines, with IC50 values below 0.3 μM. Researchers can leverage N,N-Dimethyldoxorubicin in investigations of cancer cell dynamics and drug resistance mechanisms. -
Topoisomerase I/II Inhibitor
Topoisomerase I/II inhibitor 2 is a potent inhibitor targeting both DNA topoisomerase I and II, demonstrating an IC50 of 9.82 μM in Huh7 cells and 6.83 μM in LM9 cells. This compound effectively reduces xenograft tumor growth in murine models, highlighting its potential utility in liver cancer research. Its dual inhibition mechanism provides a valuable tool for investigating therapeutic strategies in oncology. -
Topoisomerase Inhibitor
Topoisomerase Inhibitor 3 is a potent inhibitor of topoisomerase enzymes, which are crucial for DNA replication and repair. This compound has demonstrated significant antiproliferative and anti-tumor activity, making it a valuable tool for cancer research. Its ability to interfere with DNA processes positions it as a promising candidate for studying cancer cell biology and therapeutic interventions. -
Topoisomerase Inhibitor
3,6-Diamino-9(10H)-acridone is a potent topoisomerase inhibitor that interferes with the activity of the enzyme, impacting DNA replication and repair processes. Its ability to disrupt topoisomerase function makes it valuable for studying mechanisms of action in cancer biology and therapeutic resistance. This compound is useful in research applications aimed at understanding the role of topoisomerases in cellular processes and developing novel anticancer strategies. -
Anticancer agent
Anticancer agent 218 (P136) is a Camptothecin derivative that primarily targets DNA topoisomerase I, inhibiting its activity and thereby disrupting DNA replication and transcription processes. This compound exhibits potent anticancer activity, making it suitable for research applications focused on cancer cell proliferation and treatment resistance mechanisms. Its role in modulating cellular responses to chemotherapeutic agents further underscores its potential in cancer research and drug development investigations. -
DNA Topoisomerase II Inhibitor
Nidulalin A is a selective inhibitor of DNA topoisomerase II, exhibiting an IC50 value of 2.2 μM. Additionally, it demonstrates significantly less activity against DNA topoisomerase I, with an IC50 of 172 μM. Due to its DNA-damaging effects, Nidulalin A shows notable cytotoxicity, making it a valuable compound for research in cancer biology and drug development. -
Topoisomerase I/II Inhibitor
Intoplicine dimesylate is a potent inhibitor of DNA topoisomerase I and II. This compound, a derivative of the 7H-benzo[e]pyrido[4,3-b]indole series, exerts its antitumor effects by strongly binding to DNA, resulting in an increased length of linear DNA. Intoplicine dimesylate is useful in cancer research and studies involving DNA topology. -
Topo I Inhibitor
SN-398 is a potent inhibitor of mammalian DNA topoisomerase I (Topo I), functioning by stabilizing the Topo I-DNA complex and preventing DNA rewiring, which leads to Topo I-mediated DNA breaks. This derivative of Camptothecin demonstrates enhanced antitumor activity compared to SN-38, with an IC50 value of 1.562 μM in HeLa cell assays. SN-398 serves as a valuable tool for investigating the mechanisms of anti-proliferation and growth inhibition related to Topo I in various cancer cell models. -
Topoisomerase I Inhibitor
Topoisomerase I inhibitor 7 is a potent inhibitor of the enzyme topoisomerase I, demonstrating significant antitumor activity. This compound has shown to inhibit tumor growth by up to 79% and enhance the lifespan of P388 lymphoma-bearing mice by 153%. Its structure suggests promising avenues for the development of new antitumor agents derived from heteroarene-fused anthraquinones, making it a valuable tool for cancer research. -
Camptothecin Analog
TLC388 is a novel camptothecin analog targeting topoisomerase I, exhibiting potential antitumor activity in metastatic neuroendocrine carcinoma (NEC). Its unique chemical structure enhances its efficacy in disrupting DNA replication and transcription processes. This compound is valuable for research applications focused on understanding camptothecin derivatives in cancer therapy and exploring mechanisms of drug resistance in NECs. -
Topoisomerase I/II Inhibitor
Topoisomerase I/II Inhibitor 7 is a potent inhibitor targeting both topoisomerase I and II enzymes. This compound disrupts the enzymatic activity essential for DNA replication and repair, making it a valuable tool for studying mechanisms of cancer cell proliferation and drug resistance. Its applications extend to cancer research, where it can aid in the development of therapeutic strategies targeting topoisomerase activity. -
Topoisomerase I Inhibitor
Chimmitecan, a potent topoisomerase I inhibitor, represents a novel 9-small-alkyl-substituted lipophilic camptothecin derivative. This compound demonstrates significant anticancer activity, making it valuable for research focused on cancer therapies and mechanisms of drug resistance. Its ability to interfere with DNA topology positions Chimmitecan as a key tool in the study of tumor biology and the development of targeted cancer treatments. -
Topoisomerase Inhibitor
(R)-Amrubicin is a topoisomerase II inhibitor and an anthracycline derivative that intercalates into DNA, effectively disrupting DNA replication and impeding RNA and protein synthesis. This results in significant inhibition of cell growth and induction of apoptosis, making it a promising candidate for lung cancer treatment. Notably, (R)-Amrubicin demonstrates enhanced anti-tumor efficacy relative to traditional anthracyclines and exhibits a reduced risk of cumulative cardiac toxicity, providing a safer alternative for cancer therapy. -
Topoisomerase Inhibitor
NBTIs-IN-6 is a potent bacterial topoisomerase inhibitor that exhibits significant antibacterial activity. Notably, it demonstrates an MIC90 of 2 μg/mL against fluoroquinolone-resistant Methicillin-resistant Staphylococcus aureus (MRSA). This compound is valuable for research applications aimed at understanding bacterial resistance mechanisms and developing new antimicrobial therapies. -
Topo II Inhibitor
Topoisomerase II inhibitor 12 is a selective inhibitor of topoisomerase II, functioning as a DNA non-intercalator. It exhibits significant antineoplastic activity, making it a valuable reagent in cancer research. This compound is suitable for studies focused on elucidating the mechanisms of action of topoisomerase II inhibitors and their therapeutic potential in oncology. -
Human DNA topoisomerase II Inhibito
MSN8C is a novel catalytic inhibitor of human DNA topoisomerase II. This compound induces apoptosis in cancer cells and demonstrates significant anti-tumor activity in vitro. MSN8C can be utilized in research applications focused on cancer biology and therapeutic development targeting topoisomerase II pathways.
